Marksans Pharma Share Price Prediction 2027: Scenario Targets, Valuation and Technical Outlook
- October 9, 2026
- Posted by: Neeraj Pandey
- Category: Market
CMP Rs 309.00 (9 Oct 2026). 52W range Rs 155.00 to Rs 350.95. PE 26.77. 2027 base Rs 354, bull Rs 425.
Quick Answer
The Marksans Pharma share price forecast for 2027 centres on a conservative case of Rs 339, a base case of Rs 354 and a bull case of Rs 425, against a current price of Rs 309.00. These targets scale today’s price by reported EPS growth at a constant PE multiple, so they rest on earnings the company has already delivered, not on broker forecasts. The base case implies 14.6% upside from today’s price. The daily technical setup reads neutral.
Marksans Pharma share price prediction 2027 comes down to earnings growth and the multiple investors pay for it, and the reported numbers give a measured answer. The stock trades at Rs 309.00 on NSE as of 9 October 2026, 12.0% below its 52-week high of Rs 350.95, after the company reported net profit of Rs 420.06 crore for FY26.
This Marksans Pharma stock forecast 2027 builds conservative, base and bull scenarios from exchange-reported financials, shareholding data and daily price indicators, with every assumption shown.
Click Here – Get Free Investment Predictions
Marksans Pharma Share Price Today and Key Data
The Marksans Pharma share price today is Rs 309.00 on NSE, up 0.39% on the day. The market capitalisation stands at Rs 13,953 crore. Over the past year the price has risen 82.3% from Rs 169.46. Every Marksans Pharma stock forecast figure below starts from this price.
| Metric | Value |
|---|---|
| Company | Marksans Pharma (MARKSANS) |
| Current Price | Rs 309.00 |
| 52-Week High | Rs 350.95 (24 September 2026) |
| 52-Week Low | Rs 155.00 (30 March 2026) |
| Market Cap | Rs 13,953 crore |
| PE Ratio | 26.77 |
| Industry PE | 37.59 |
| PB Ratio | 4.62 |
| EPS (TTM) | Rs 11.50 |
| Return on Equity | 13.82% |
| Debt to Equity | 0.11 |
| Dividend Yield | 0.29% |
| Book Value per Share | Rs 66.71 |
What Is the Marksans Pharma Share Price Prediction for 2027?
The Marksans Pharma share price prediction for 2027 is a conservative case of Rs 339, a base case of Rs 354 and a bull case of Rs 425. Against Rs 309.00, these imply 9.7% upside, 14.6% upside and 37.5% upside. They are model scenarios built from reported EPS growth, not broker targets.
| Scenario | EPS Growth Basis | EPS Estimate | PE Multiple | Implied Value | Upside vs Current Price |
|---|---|---|---|---|---|
| Conservative Case | Lower of FY26 growth (9.8%) and 4-year CAGR (19.6%) | Rs 12.62 (+9.8%) | Unchanged from today (price to EPS ratio kept constant) | Rs 339 | +9.7% |
| Base Case | Average of the two | Rs 13.19 (+14.7%) | Unchanged from today (price to EPS ratio kept constant) | Rs 354 | +14.6% |
| Bull Case | Higher of the two | Rs 13.75 (+19.6%) | Re-rated 15.0% toward industry PE of 37.59 (still at or below it) | Rs 425 | +37.5% |
Each target takes today’s price of Rs 309.00 and scales it by the EPS growth assumed for that case, which is the same as holding the PE multiple constant. The conservative case uses the lower of the FY26 EPS growth and the 4-year EPS CAGR, the base case uses their average and the bull case uses the higher figure. The bull case also re-rates the PE multiple toward the industry level, because the stock trades below it. Together they form the Marksans Pharma target price range for the FY27 outlook over the next 12 months, and the range is not a point estimate.
Marksans Pharma Share Price Forecast: What Has to Go Right by 2027
Each Marksans Pharma target price below depends on a specific EPS outcome, and the text states that outcome next to the number.
Conservative Case for the Marksans Pharma Share Price Target: Rs 339
Reaching Rs 339 needs EPS to rise 9.8% to Rs 12.62 while the stock keeps its current PE multiple. That matches the FY26 EPS growth of 9.8%.
Base Case for the Marksans Pharma Share Price Target: Rs 354
Reaching Rs 354 needs EPS to rise 14.7% to Rs 13.19, the average of the FY26 growth rate and the 4-year CAGR. Net profit growth of 173.9% in Q1 FY27 is at or above that pace, which supports the target.
Bull Case for the Marksans Pharma Share Price Target: Rs 425
Reaching Rs 425 needs EPS to rise 19.6% to Rs 13.75 and the PE multiple to re-rate 15.0% toward the industry PE. That is above the 52-week high of Rs 350.95, so it would need a fresh breakout. A daily close above the nearest resistance level of Rs 315.95 (50-day SMA) would be the first technical confirmation.
Marksans Pharma Financial Performance: Revenue, Profit and Margins
Marksans Pharma earned net profit of Rs 420.06 crore on revenue of Rs 3,033.47 crore in FY26, with profit up 9.8% and revenue up 12.8% compared with FY25. Diluted EPS was Rs 9.22 against Rs 8.40 a year earlier, and that earnings base anchors the Marksans Pharma share price forecast.
| Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Operating Margin | Net Margin |
|---|---|---|---|---|---|
| FY22 | 1,532.69 | 186.81 | 4.51 | 20.17% | 12.19% |
| FY23 | 1,911.45 | 265.32 | 6.41 | 21.52% | 13.88% |
| FY24 | 2,227.83 | 314.89 | 6.92 | 23.38% | 14.13% |
| FY25 | 2,689.17 | 382.62 | 8.40 | 22.84% | 14.23% |
| FY26 | 3,033.47 | 420.06 | 9.22 | 23.16% | 13.85% |
In the latest reported quarter, Q1 FY27 (quarter ended June 2026), revenue was Rs 866.20 crore against Rs 625.63 crore a year earlier (+38.5%), and the bottom line was a net profit of Rs 159.41 crore against a net profit of Rs 58.20 crore (+173.9%). Operating margin was 28.36% versus 17.06% in the year-ago quarter. Cash flow from operations was Rs 458.13 crore in FY26 against Rs 206.66 crore in FY25. Together these figures set the earnings base for the Marksans Pharma share price prediction.
Check the Univest Screener for live Marksans Pharma fundamentals
Is Marksans Pharma Overvalued or Undervalued Right Now?
Marksans Pharma trades at a PE of 26.77 against an industry PE of 37.59, which places the stock at a 28.8% discount to the industry average. The price-to-book ratio is 4.62 on a book value of Rs 66.71 per share. Return on equity of 13.82% means the company earns Rs 13.82 of profit for every Rs 100 of shareholder equity.
Debt to equity is 0.11, so borrowings equal about 11% of shareholder equity. The company declared a dividend of Rs 0.90 per share for FY26, a yield of 0.29% at the current price. This valuation context frames the Marksans Pharma stock price prediction for 2027 without relying on any outside forecast.
Marksans Pharma Stock Analysis: Technical Outlook
Marksans Pharma stock trades below its 50-day SMA of Rs 315.95 and above its 200-day EMA of Rs 255.99, and the combined daily indicators read neutral. The 52-week high of Rs 350.95 was set on 24 September 2026, while the 52-week low of Rs 155.00 came on 30 March 2026.
| Indicator | Reading | Signal |
|---|---|---|
| RSI (14) | 45.78 | Neutral |
| MACD (12,26,9) | -0.04 vs signal 3.76 | Bearish |
| ADX (14) | 11.31 | Weak trend |
| Supertrend (10,3) | Price above Rs 300.97 | Bullish |
| 50-day SMA | Rs 315.95 | Price below |
| 200-day EMA | Rs 255.99 | Price above |
The nearest support level sits at Rs 300.97 (Supertrend) and Rs 255.99 (200-day EMA). The nearest resistance level sits at Rs 315.95 (50-day SMA) and Rs 350.95 (52-week high). A sustained move above the nearest resistance would support the Marksans Pharma share price prediction 2027 base case, and this Marksans Pharma stock analysis uses daily candles only.
Marksans Pharma Shareholding Pattern
Promoters hold 43.87% of Marksans Pharma as of Jun 2026, unchanged across the last 5 quarters. FII holding is 17.47% (down from 19.88% in Jun 2025) and DII holding is 6.19% (up from 5.50% in Jun 2025), which puts combined institutional holding at 23.66%. Public shareholders own 32.47%. Shareholding data is one input for any Marksans Pharma stock forecast.
Key Risks to the Marksans Pharma Share Price Target for 2027
Earnings and Margin Risk
Operating margin has ranged from 20.17% to 23.38% between FY22 and FY26, so a slip toward the lower end would trim the EPS estimate behind the Marksans Pharma stock forecast. Revenue was up 12.8% in FY26, and slower revenue growth would weigh on the profit path.
Size and Liquidity Risk
Market capitalisation stands at Rs 13,953 crore. Investors should check daily traded volumes and order book depth on NSE before sizing a position, because price moves can be sharper when volumes thin out. Liquidity is a practical constraint on any Marksans Pharma stock price target.
Balance Sheet Risk
Debt to equity of 0.11 means borrowings stand at about 11% of shareholder equity. A rise in borrowing costs or a jump in debt would weigh on profit and on the multiple behind the Marksans Pharma share price forecast.
Conclusion
This Marksans Pharma stock analysis puts the share price target range for 2027 at Rs 339 to Rs 425, with a base case of Rs 354 against Rs 309.00 today. The inputs are a PE of 26.77 that sits at a 28.8% discount to the industry average, EPS growth of 9.8% in FY26 and a daily technical setup that reads neutral. The next quarterly result will show which scenario is gaining ground. This analysis is educational, so consult a SEBI-registered advisor before acting on it.
Download the Univest iOS App or Univest Android App to track Marksans Pharma live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Marksans Pharma Share Price Prediction 2027
What is the Marksans Pharma share price target for 2027?
Ans. The Marksans Pharma share price forecast for 2027 has a conservative case of Rs 339, a base case of Rs 354 and a bull case of Rs 425. These are model scenarios based on reported EPS growth, and they are not guaranteed outcomes.
What is the Marksans Pharma share price today?
Ans. Marksans Pharma trades at Rs 309.00 on NSE as of 9 October 2026, up 0.39% on the day. The 52-week range is Rs 155.00 to Rs 350.95.
Is Marksans Pharma a good stock to buy for 2027?
Ans. The data points in different directions: the PE of 26.77 is at a 28.8% discount to the industry average, EPS grew 9.8% in FY26 and the daily technical setup reads neutral. This article does not constitute investment advice, so consult a SEBI-registered advisor before deciding.
Can Marksans Pharma stock reach Rs 425 in 2027?
Ans. Reaching Rs 425 needs EPS to rise 19.6% from Rs 11.50 and the PE multiple to re-rate toward the industry PE of 37.59, plus a daily close above Rs 315.95 (50-day SMA). This is a scenario, not a guarantee.
What are the support and resistance levels for Marksans Pharma?
Ans. The nearest support levels are Rs 300.97 (Supertrend) and Rs 255.99 (200-day EMA), and the nearest resistance levels are Rs 315.95 (50-day SMA) and Rs 350.95 (52-week high).
What are the main risks for Marksans Pharma stock in 2027?
Ans. The main risks to the Marksans Pharma share price forecast are a fall in operating margin from the 20.17% to 23.38% range seen since FY22, slower revenue growth after FY26 revenue was up 12.8%, and thin trading volumes. Debt to equity of 0.11 adds balance sheet sensitivity.
How is the Marksans Pharma target price for 2027 calculated?
Ans. Each target scales the current price by assumed EPS growth at a constant PE multiple. The conservative case uses 9.8% growth, the base case 14.7% and the bull case 19.6%, all drawn from the company’s reported FY26 and 4-year EPS growth.
